# PULSAR Combined With Immunotherapy and Chemotherapy

> **NCT07291947** · PHASE1,PHASE2 · RECRUITING · sponsor: **Wang Xin** · enrollment: 60 (estimated)

## Conditions studied

- Cholangiocarcinoma

## Interventions

- **DRUG:** Iparomlimab and Tuvonralimab Injection (QL1706)
- **RADIATION:** PULSAR

## Key facts

- **NCT ID:** NCT07291947
- **Lead sponsor:** Wang Xin
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-11-04
- **Primary completion:** 2026-09-10
- **Final completion:** 2027-09-10
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2025-12-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07291947

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07291947, "PULSAR Combined With Immunotherapy and Chemotherapy". Retrieved via AI Analytics 2026-07-01 from https://api.ai-analytics.org/clinical/NCT07291947. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*